|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Vanderbilt University |
|---|---|
| Information provided by: | Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT00608465 |
Purpose
The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. It can also lead to the early development of hardening of the arteries and increased risk of a stroke. This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.
| Condition | Intervention | Phase |
|---|---|---|
|
Metabolic Syndrome X |
Drug: Eplerenone Drug: Ramipril |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity |
| Estimated Enrollment: | 60 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | May 2011 |
| Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Treatment A: Active Comparator
Eplerenone (study drug)
|
Drug: Eplerenone
5 mg x 1 week followed by 10 mg x 9 weeks.
|
|
Treatment B: Active Comparator
Ramipril
|
Drug: Ramipril
Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
|
Obesity is an increasingly important risk factor for cardiovascular disease in men and women and is associated with the premature development of atherosclerosis, and increased risk of stroke. A classical perspective of cardiovascular risk does not adequately explain all of the cardiovascular events associated with obesity. Elevated plasma levels of plasminogen activator inhibitor type I (PAI-1) are one of the biochemical hallmarks for obesity and likely contribute the increased risk of atherothrombotic events in patients with obesity. The central hypothesis of this proposal is that the increased risk of atherothrombotic events in patients with obesity. The central hypothesis of this proposal is that vascular PAI-1 excess promotes the development of intravascular thrombosis. We will test the hypothesis that secreted factors from adipocytes have autocrine, paracrine and endocrine effects that have a deleterious effect on the fibrinolytic system, either by enhancing PAI-1 production or impairing endothelial t-PA release. From a public health perspective, there is no greater threat to America's cardiovascular health than the epidemic of obesity. It is anticipated that this study will provide new insights nto the molecular mechanisms that contribute to the development of fibrinolytic dysfunction and cardiovascular disease in obesity.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Subjects with documentation of the following health risk:
Contacts and Locations| Contact: James AS Muldowney, III, MD | 615-936-1719 | james.muldowney@vanderbilt.edu |
| United States, Tennessee | |
| Vanderbilt University Medical Center | Recruiting |
| Nashville, Tennessee, United States, 37232 | |
| Contact: James AS Muldowney, III, MD 615-936-1750 james.muldowney@vanderbilt.edu | |
| Principal Investigator: | James AS Muldowney, MD | Vanderbilt University |
More Information
| Responsible Party: | Vanderbilt University Medical Center ( James A.S. Muldowney III, MD ) |
| Study ID Numbers: | 060369, 060369 |
| Study First Received: | January 22, 2008 |
| Last Updated: | April 10, 2009 |
| ClinicalTrials.gov Identifier: | NCT00608465 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Fibrolytic Dysfunction Obesity PAI-1 |
|
Molecular Mechanisms of Pharmacological Action Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Overweight Ramipril Body Weight Hyperinsulinism Signs and Symptoms Pathologic Processes Syndrome Therapeutic Uses Nutrition Disorders Angiotensin-Converting Enzyme Inhibitors |
Obesity Disease Metabolic Syndrome X Metabolic Diseases Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Protease Inhibitors Eplerenone Aldosterone Antagonists Overnutrition Insulin Resistance Glucose Metabolism Disorders |